ClinicalTrials.gg
CompletedNCT04143815Updated Mar 19, 2021

Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines

A Phase 2 interventional study of MBA-P01 (Botulinum toxin A) and Placebo in Glabellar Frown Lines, sponsored by Medy-Tox. Completed at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-19.

Sponsored by Medy-Tox · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled May 2019, registered Oct 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will determine the effect of MBA-P01 in subjects with glabellar lines at a range of doses compared with placebo.

This study includes two treatment period; 1) Dose-ranging period, Day0 to 16weeks and 2) Open-label extension period, 16 weeks to 52.

02

Conditions studied

  • Glabellar Frown Lines
03

In context

Lead sponsor

Medy-Tox is the lead sponsor of 49 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female over 18 years of age
  • Bilaterally symmetrical moderate to severe GL at maximum frown as assessed by both investigator and subject using FWS

Exclusion criteria

Exclusion Criteria:

  • History of facial nerve paralysis
  • Any eyebrow or eyelied ptosis as determined by the investigator
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    MBA-P01 30U

    Experimental group, Dose: 30U

    Drug: MBA-P01 (Botulinum toxin A)

  • Experimental
    MBA-P01 20U

    Experimental group, Dose: 20U

    Drug: MBA-P01 (Botulinum toxin A)

  • Experimental
    MBA-P01 10U

    Experimental group, Dose: 10U

    Drug: MBA-P01 (Botulinum toxin A)

  • Placebo comparator
    Placebo

    Placebo group, Normal saline

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Facial Wrinkle Scale(FWS) change

    Proportion of subjects achieving at least a 2-grade decrease from baseline in score of Facial Wrinkle Scale (FWS) (0:none to 3: severe) of Glabellar line at maximum frown

    Time frame: 4 weeks

07

Study locations

1 site
  • Maroubra MEdical Centre
    Maroubra, New South Wales 2035, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Sep 2020, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2019
First posted
Oct 29, 2019
StartActual
May 20, 2019
Primary completionActual
Sep 1, 2020
CompletionActual
Sep 1, 2020
Last update
Mar 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04143815
Lead sponsor
Medy-Tox
Responsible party
Sponsor
First posted
Oct 29, 2019
Start date
May 20, 2019
Primary completion
Sep 1, 2020
Completion
Sep 1, 2020
Last update
Mar 19, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion